Loading clinical trials...
Loading clinical trials...
Spironolactone for the Treatment of Melasma: a Prospective, Open-label Proof-of-concept and Dose-ranging Study
Conditions
Interventions
Spironolactone 50Mg Tablet
Spironolactone 100Mg Tablet
+1 more
Locations
1
United States
Medical University of SC
Charleston, South Carolina, United States
Start Date
March 5, 2020
Primary Completion Date
January 1, 2021
Completion Date
January 1, 2021
Last Updated
September 4, 2024
NCT06516419
NCT07296549
NCT06644157
NCT07345507
NCT06957834
NCT05326997
Lead Sponsor
Medical University of South Carolina
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions